D. Geoffrey Vince, PhD
Chair, Department of Biomedical Engineering
Cleveland Clinic Lerner Research Institute
D. Geoffrey Vince, PhD (NCAI Co-Principal Investigator) is Chair of Cleveland Clinic's Department of Biomedical Engineering (BME) in the Lerner Research Institute. Originally from the U.K., he earned dual B.Sc degrees in Medical Sciences and Chemistry from Leicester DeMontford University and his Ph.D. in Biomedical Engineering from the University of Liverpool. Coming in the early 1990s , Dr. Vince pursued research in ultrasound imaging of coronary artery disease. From 1992 to 2005, he advanced from Research Fellow to Associate Staff and developed an imaging system to capture and evaluate images of the interior of the coronary artery. As a full-time scientist, he published his research findings in such well-regarded journals as Circulation, the American Journal of Cardiology, and the International Journal of Cardiovascular Imaging, among others. He served on Study Sections for peer review of grant proposals at the National Institutes of Health and carried forward teaching and mentoring duties for students and junior investigators. In 2005, he stepped into the corporate world and gained experience over many successful years on the international front, first as Director of Research, then Vice President for Clinical and Advanced R&D for Volcano Corporation in San Diego. These years involved broad exposure to issues of innovation, technology transfer, industry standards, and collaborative international agreements. As of mid-2011, Dr. Vince returned to Cleveland Clinic's Lerner Research Institute as BME Chair. An inventor/co-inventor of several biomedical systems, he has filed over 60 applications and holds 12 U.S. patents. Perhaps the most notable is one based on his early efforts at Cleveland Clinic – "Virtual Histology"; this intravascular ultrasound imaging system was later refined and commercialized into what is now Volcano's "VH®" system, a widely used real-time imaging modality to visualize plaque composition within arteries. Thus his own experience is a sterling example of the aims of the NCAI: showing how research from a not-for-profit institution can be leveraged for translational/clinical applications and successfully commercialized for the betterment of patient care worldwide.
End of main page content.